Urinary neopterin, hemoglobin and peripheral blood cell counts in breast carcinoma patients treated with dose-dense chemotherapy

Anticancer Research

Volumn 28, Issue 4 C, 2008, Pages 2389-2396

  Melichar, Bohuslav ^a,c   Urbánek, Lubor ^a,b   Krčmová, Lenka ^a,b   Kalábová, Hana ^a   Melicharová, Karolina ^a   Malířová, Eva ^a   Hornychová, Helena ^a   Ryška, Aleš ^a   Hyšpler, Radomír ^a   Solichovǎ, Dagmar ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

^b Charles University in Prague Faculty of Pharmacy   (Czech Republic)

^c PALACKÝ UNIVERSITY   (Czech Republic)

Author keywords

Breast carcinoma; Chemotherapy; Cyclophosphamide; Doxorubicin; Ferritin; Iron; Neopterin; Paclitaxel

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; FERRITIN; HEMOGLOBIN; IRON; NEOPTERIN; PACLITAXEL; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; AGED; ARTICLE; BLOOD CELL COUNT; BREAST CARCINOMA; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; DRUG DOSE SEQUENCE; FEMALE; FERRITIN BLOOD LEVEL; HEMOGLOBIN DETERMINATION; HUMAN; IRON METABOLISM; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; PREDICTION; PRIORITY JOURNAL; PROTEIN URINE LEVEL; THERAPY EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE;

EID: 48849102214     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Veronesi U, Boyle P, Goldhirsch A, Orecchia R and Viale G: Breast cancer. Lancet 365: 1727-1741, 2005.
2. Early Breast Cancer Trialists Collaborative Group: Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365: 1687-1717, 2005.
3. Fisher B, Brown A, Mamounas E, Wieand S, Robidoux A, Margolese RG, Cruz AB, Fisher ER, Wickerham DL, Wolmark N, DeCillis A, Hoehn JL, Lees AW and Dimitrov NV: Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol 15: 2483-2493,1997.
4. Fisher B, Bryant J, Wolmark N, Mamounas E, Brown A, Fisher ER, Wickerham DL, Begovic M, DeCillis A, Robidoux A, Margolese RG, Cruz AB, Hoehn JL, Lees AW, Dimitrov NV and Bear HD: Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 16: 2672-2685,1998.
5. van der Hage JA, van de Velde CJH, Julien JP, Tubiana-Hulin M, Vandervelden C and Duchateau L: Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer trial 10902. J Clin Oncol 19: 4224-4237, 2001.
6. Mauri D, Pavlidis N and Ioannidis JPA: Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis. J Natl Cancer Inst 97: 188-194, 2005.
7. Citron ML, Berry DA, Cirrincione C, Hudis C, Winer EP, Gradishar WJ, Davidson NE, Martino S, Livingston R, Ingle JN, Perez EA, Carpenter J, Kurd D, Holland JF, Smith BL, Sartor CI, Leung EH, Abrams J, Schilsky RL, Muss HB and Norton L: Randomized trial, of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup trial C9741/Cancer and Leukemia Group B trial 9741. J Clin Oncol 21: 1431-1439,2003.
8. Green MC, Buzdar AU, Smith T, Ibrahim NK, Valero V, Rosales MF, Cristofanilli M, Booser DJ, Pusztai L, Rivera E, Theriault RL, Carter C, Frye D, Hunt KK, Symmans WF, Strom EA, Sahin AA, Sikov W and Hortobagyi GN: Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeks. J Clin Oncol 23: 5983-5992, 2005.
9. Pusztai L, Mendoza TR, Reuben JM, Martinez MM, Willey JS, Lara J, Syed A, Fritsche HA, Bruera E, Booser D, Valero V, Arun B, Ibrahim N, Edgardo R, Royce M, Cleeland CS and Hortobagyi GN: Changes in plasma levels of inflammatory cytokines in response to paclitaxel chemotherapy. Cytokine 25: 94-102,2004.
10. Tsavaris N, Kosmas C, Vadiaka M, Kanelopoulos P and Boulamatsis D: Immune changes in patients with advanced breast cancer undergoing chemotherapy with taxanes. Br J Cancer 87: 21-27,2002.
11. Melichar B, Solichova D and Freedman RS: Neopterin as an indicator of immune activation and prognosis in patients with gynecological malignancies. Int J Gynecol Cancer 16: 240-252, 2006.
12. Melichar B, Solichova D, Melicharova K, Cermanova M, Urminska H and Ryska A: Systemic immune activation, anemia and thrombocytosis in breast cancer patients treated by doxorubicin and paclitaxel. Pteridines 17: 107-114, 2006.
13. Chevallier B, Roche H, Olivier JP, Chollet P and Hurteloup P: Inflammatory breast cancer. Pilot study of intensive induction chemotherapy (FEC-HD) results in high histologic response rate. Am J Clin Oncol 16: 223-228, 1993.
14. Melichar B, Kalabova H, Urbanek L, Malirova E and Solichova D: Serial urinary neopterin measurements reflect the disease course in patients with epithelial ovarian carcinoma treated with paclitaxel/platinum. Pteridines 18: 1-7, 2007.
15. Solichova D, Melichar B, Blaha V, Klejna M, Vavrova J, Palicka V and Zadak Z: Biochemical profile and survival in nonagenarians. Clin Biochem 34: 563-569, 2001.
16. Reibnegger G, Fuchs D, Fuith LC, Hausen A, Werner ER, Werner-Felmayer G and Wachter H: Neopterin as a marker for activated cell-mediated immunity: application in malignant disease. Cancer Detect Prev 15: 483-490, 1991.
17. Murr C, Berant A, Widschwendter M, Heim K, Schrocksnadel H and Fuchs D: Neopterin is an independent prognostic variable in females with breast cancer. Clin Chem 45: 1998-2004,1999.
18. Bower JE, Ganz PA, Aziz N, Fahey JL and Cole SW: Fatigue and proinflammatory cytokine activity in breast cancer survivors. Psychosom Med 64: 604-611, 2002.
19. Melichar B, Touskova M, Hornychova H, Vokurkova D, Solichova D, Vesely P, Mergancova J, Urminska H and Ryska A: Systemic immune activation and peripheral blood lymphocytes during primary chemotherapy with the combination of doxorubicin and paclitaxel. Pteridines 18: 25-34,2007.
20. Bogdan C and Ding A: Taxol, a microtubule-stabilizing antineoplastic agent, induces expression of tumor necrosis factor alpha and interleukin-1 in macrophages. J Leukocyte Biol 52: 119-121,1992.
21. Allen JN, Moore SA and Wewers MD: Taxol enhances but does not induce interleukin-1 beta and tumor necrosis factor-alpha production. J Lab Clin Med 122: 374-381, 1993.
22. Mullins DW, Burger CJ and Elgert KD: Paclitaxel enhances macrophage IL-12 production in tumor-bearing hosts through nitric oxide. J Immunol 162: 6811-6818, 1999.
23. Wachter H, Fuchs D, Hausen A, Reibnegger G and Werner ER: Neopterin as marker for activation of cellular immunity: immunologic basis and clinical application. Adv Clin Chem 27: 81-141,1989.
24. Bower JE, Ganz PA, Aziz N, Fahey JL and Cole SW: T-cell homeostasis in breast cancer survivors with persistent fatigue. J Natl Cancer Inst 95: 1165-1168, 2003.
25. Groopman JE and Itri LM: Chemotherapy-induced anemia in adults: incidence and treatment. J Natl Cancer Inst 91: 1616-1634,1999.
26. Denz H, Fuchs D, Huber H, Nachbaur D, Reibnegger G, Thaler J, Werner ER and Wachter H: Correlation between neopterin, interferon-gamma and haemoglobin in patients with haematological disorders. Eur J Haematol 44: 186-189, 1990.
27. Wachter H, Artner-Dworzak E, Fuchs D, Fuith LC, Hausen A, Reibnegger G, Werner ER, Werner-Felmayer G and Dierich MP: Association between neopterin and iron metabolism in cancer patients. Tumor Diagn Ther 11: 229-232, 1990.
28. Fuchs D, Hausen A, Reibnegger G, Werner ER, Werner-Felmayer G, Dierich M and Wachter H: Immune activation and the anaemia associated with chronic inflammatory disorders. Eur J Haematol 46: 65-70, 1991.
29. Hausen A, Fuchs D, Reibnegger G, Werner ER, Werner-Felmayer G and Wachter H: Reduction of ferric iron by 7, 8-dihydronepterin. Pteridines 2: 83-85, 1990.
30. Muenchen HJ and Aggarwal SK: Activation of murine peritoneal macrophages after cisplatin and taxol combination. Anticancer Drugs 8: 784-789, 1997.
31. Miranda CJ, Makui H, Scares RJ, Bilodeau M, Mui J, Vali H, Bertrand R, Andrews NC and Santos MM: Hfe deficiency increases susceptibility to cardiotoxicity and exacerbates changes in iron metabolism induced by doxorubicin. Blood 102: 2574-2580, 2003.
32. Kwok JC and Richardson DR: Anthracyclines induce accumulation of iron in ferritin in myocardial and neoplastic cells: inhibition of the ferritin iron mobilization pathway. Mol Pharmacol 63: 849-861, 2003.
33. Ulbrich EJ, Lebrecht A, Schneider I, Ludwig E, Koelbl H and Hefler LA: Serum parameters of iron metabolism in patients with breast cancer. Anticancer Res 23: 5107-5110, 2003.
34. Williams MR, Turkes A, Pearson D, Griffiths K and Blarney RW: Serum ferritin as a marker of therapeutic response in stage III and IV breast cancer. Eur J Surg Oncol 16: 22-27, 1990.
35. Chollet P, Amat S, Cure H, de Latour M, Le Bouedec G, Mouret-Reynier MA, Ferriere JP, Achard JL, Dauplat J and Penault-Llorca F: Prognostic significance of a complete pathological response after induction chemotherapy in operable breast cancer. Br J Cancer 86: 1041-1046, 2002.
36. Bear HD, Anderson S, Smith RE, Geyer CE, Mamounas EP, Fischer B, Brown AM, Robidoux A, Margolese R, Kahlenberg MS, Paik S, Soran A, Wickerham DL and Wolmark N: Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National Surgical Adjuvant Breast and Bowel Project protocol B-27. J Clin Oncol 24: 2019-2027, 2006.
37. Machiavelli MR, Romero AO, Ferez JE, Lacava JA, Dominguez ME, Rodriguez R, Barbieri MR, Acuna LAR, Acuna JMR, Langhi MJ, Amato S, Ortiz EH, Vllejo CT and Leone BA: Prognostic significance of pathological response of primary tumor and metastatic axillary lymph nodes after neoadjuvant chemotherapy for locally advanced breast carcinoma. Cancer J Sci Am 4: 125-131,1998.
38. Thomas E, Holmes FA, Smith TL, Buzdar AU, Frye DK, Fraschini G, Singletary SE, Theriault RL, McNeese MD, Ames F, Walters R and Hortobagyi GN: The use of alternate, non-cross-resistant adjuvant chemotherapy on the basis of pathologic response to a neoadjuvant doxorubicin-based regimen in women with operable breast cancer: long-term results from a prospective randomized trial. J Clin Oncol 22: 2294-2302, 2004.
39. Cermak J, Balla J, Jacob HS, Balla G, Enright H, Nath K and Vercellotti GM: Tumor cell heme uptake induces ferritin sythesis resulting in altered oxidant sensitivity: possible role in chemotherapy efficacy. Cancer Res 53: 5308-5313, 1993.